Lignes directrices de pratique clinique 2008 de l - Canadian ...

S134 | liGnes direCtriCes de pratiQue CliniQue 2008
incidence and location in the GUSTO-I trial. Global Utilization
of Streptokinase and t-PA for Occluded Coronary Arteries. J Am
Coll Cardiol. 1997;30:1606-1610.
24. Ishihara M, Kojima S, Sakamoto T, et al. Acute hyperglycemia
is associated with adverse outcome after acute myocardial
infarction in the coronary intervention era. Am Heart J.
2005;150:814-820.
25. Hadjadj S, Coisne D, Mauco G, et al. Prognostic value of admission
plasma glucose and HbA in acute myocardial infarction.
Diabet Med. 2004;21:305-310.
26. Ainla T, Baburin A, Teesalu R, et al. The association between
hyperglycaemia on admission and 180-day mortality in acute
myocardial infarction patients with and without diabetes. Diabet
Med. 2005;22:1321-1325.
27. Almbrand B, Johannesson M, Sjostrand B, et al. Cost-effectiveness
of intense insulin treatment after acute myocardial infarction in
patients with diabetes mellitus; results from the DIGAMI study.
Eur Heart J. 2000;21:733-739.
28. Davies MJ, Lawrence IG. DIGAMI (Diabetes Mellitus, Insulin
Glucose Infusion in Acute Myocardial Infarction): theory and
practice. Diabetes Obes Metab. 2002;4:289-295.
29. Malmberg K. Prospective randomised study of intensive insulin
treatment on long term survival after acute myocardial infarction
in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus,
Insulin Glucose Infusion in Acute Myocardial Infarction) Study
Group. BMJ. 1997;314:1512-1515.
30. Malmberg K, Ryden L, Hamsten A, et al. Effects of insulin treatment
on cause-specific one-year mortality and morbidity in diabetic
patients with acute myocardial infarction. DIGAMI Study
Group. Diabetes Insulin-Glucose in Acute Myocardial Infarction.
Eur Heart J. 1996;17:1337-1344.
31. Malmberg KA, Efendic S, Ryden LE. Feasibility of insulin-glucose
infusion in diabetic patients with acute myocardial infarction. A
report from the multicenter trial: DIGAMI. Diabetes Care. 1994;
17:1007-1014.
32. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose
infusion followed by subcutaneous insulin treatment
in diabetic patients with acute myocardial infarction (DIGAMI
study): effects on mortality at 1 year. J Am Coll Cardiol. 1995;26:
57-65.
33. Malmberg K, Ryden L, Wedel H, et al; DIGAMI Investigators.
Intense metabolic control by means of insulin in patients with diabetes
mellitus and acute myocardial infarction (DIGAMI 2): effects
on mortality and morbidity. Eur Heart J. 2005;26:650-661.
34. Cheung NW, Wong VW, McLean M. The Hyperglycemia:
Intensive Insulin Infusion in Infarction (HI-5) study: a randomized
controlled trial of insulin infusion therapy for myocardial
infarction. Diabetes Care. 2006;29:765-770.
35. Gustafsson I, Torp-Pedersen C, Kober L, et al. Effect of the angiotensin-converting
enzyme inhibitor trandolapril on mortality and
morbidity in diabetic patients with left ventricular dysfunction
after acute myocardial infarction. Trace Study Group. J Am Coll
Cardiol. 1999;34:83-89.
36. Borghi C, Bacchelli S, Esposti DD, et al; SMILE Study. Effects of
the early ACE inhibition in diabetic nonthrombolyzed patients
with anterior acute myocardial infarction. Diabetes Care.
2003;26:1862-1868.
37. Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial
infarction: systematic review and meta regression analysis.
BMJ. 1999;318:1730-1737.
38. Kjekshus J, Gilpin E, Cali G, et al. Diabetic patients and beta-blockers
after myocardial infarction. Eur Heart J. 1990;11:43-50.
39. Dargie HJ. Effect of carvedilol on outcome after myocardial
infarction in patients with left-ventricular dysfunction: the
CAPRICORN randomised trial. Lancet. 2001;357:1385-1390.
40. Younis N, Burnham P, Patwala A, et al. Beta blocker prescribing
differences in patients with and without diabetes following a first
myocardial infarction. Diabet Med. 2001;18:159-161.
41. Alter DA, Khaykin Y, Austin PC, et al. Processes and outcomes of
care for diabetic acute myocardial infarction patients in Ontario:
do physicians undertreat? Diabetes Care. 2003;26:1427-1434.
42. Franklin K, Goldberg RJ, Spencer F, et al. Implications of diabetes
in patients with acute coronary syndromes. The Global Registry of
Acute Coronary Events. Arch Intern Med. 2004;164:1457-1463.
43. Eagle KA, Goodman SG, Avezum A, et al. Practice variation and
missed opportunities for reperfusion in ST-segment-elevation
myocardial infarction: findings from the Global Registry of Acute
Coronary Events (GRACE). Lancet. 2002;359:373-377.
44. Ohman EM, Roe MT, Smith SC Jr., et al; CRUSADE Investigators.
Care of non-ST-segment elevation patients: insights from the
CRUSADE national quality improvement initiative. Am Heart J.
2004;148(5 suppl):S34-S39.
45. Norhammar A, Malmberg K, Ryden L, et al. Under utilisation of
evidence-based treatment partially explains for the unfavourable
prognosis in diabetic patients with acute myocardial infarction.
Eur Heart J. 2003;24:838-844.
46. Yan RT, Yan AT, Tan M, et al; Canadian Acute Coronary
Syndrome Registry Investigators. Underuse of evidence-based
treatment partly explains the worse clinical outcomes in diabetic
patients with acute coronary syndromes. Am Heart J. 2006;152:
676-683.
47. Brogan GX Jr., Peterson ED, Mulgund J, et al. Treatment disparities
in the care of patients with and without diabetes presenting
with non-ST-segment elevation acute coronary syndromes.
Diabetes Care. 2006;29:9-14.